Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Neuroscience

Alto launches with deep neuroscience pipeline

by Michael McCoy
October 23, 2021 | A version of this story appeared in Volume 99, Issue 39

 

Alto Neuroscience has emerged from stealth with $40 million in funding and 11 clinical-stage experimental drugs, which the biotech firm says is the industry’s largest such pipeline of precision psychiatry medicines. Founded quietlyin 2019 by Stanford University psychiatrist and neuroscientist Amit Etkin, Alto has three compounds in Phase 2a studies for major depressive disorder and post-traumatic stress disorder. Others are for sleep and emotional disorders.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.